Quest Diagnostics Reports Strong Q2 2026 Results, Raises Full-Year Guidance

Quest Diagnostics Reports Strong Q2 2026 Results, Raises Full-Year Guidance

On July 23, 2026, Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced its financial results for the second quarter ended June 30, 2026. The company reported significant growth in both revenue and earnings, leading to an upward revision of its full-year guidance.

Second Quarter 2026 Financial Highlights

• Revenue: $3.04 billion, a 10.2% increase from the same period in 2025.
• Organic Revenue Growth: 10.0%, indicating strong performance excluding acquisitions.
• Reported Diluted Earnings Per Share (EPS): $2.84, up 15.0% from Q2 2025.
• Adjusted Diluted EPS: $3.12, a 19.1% increase from the prior year.

These results surpassed analyst expectations, with adjusted EPS exceeding the consensus estimate of $2.82 by $0.30, and revenue surpassing the anticipated $2.97 billion. Following the announcement, Quest Diagnostics’ stock rose by approximately 5% in pre-market trading.

Revised Full-Year 2026 Guidance

In light of the strong second-quarter performance, Quest Diagnostics has updated its full-year 2026 guidance:

• Revenue: Now expected to be between $11.95 billion and $12.05 billion.
• Reported Diluted EPS: Projected between $9.97 and $10.17.
• Adjusted Diluted EPS: Anticipated between $11.05 and $11.25.

This marks an increase from the previous guidance, reflecting the company’s confidence in its ongoing growth trajectory.

CEO’s Statement

Jim Davis, Chairman, CEO, and President of Quest Diagnostics, commented on the results:

“Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health.”

Market Reaction

The positive financial results and raised guidance have been well-received by investors. As of July 24, 2026, Quest Diagnostics’ stock (DGX) is trading at $227.86, reflecting a slight decrease of 0.06% from the previous close. The stock’s performance indicates investor confidence in the company’s strategic direction and financial health.

Conclusion

Quest Diagnostics’ strong second-quarter performance and optimistic full-year outlook underscore its position as a leader in the diagnostic information services sector. The company’s ability to achieve significant organic growth and exceed earnings expectations highlights its effective strategic execution and commitment to delivering value to shareholders.